Biogen loses edge on blockbuster rare disease market with Novartis' FDA approval

Allison DeAngelis
Biogen loses edge on blockbuster rare disease market with Novartis' FDA approval

Biogen has new competition: Swiss pharma giant Novartis received FDA approval Friday for a spinal muscular atrophy drug that can stave off and potentially cure the disease with a single treatment.